Listed

IGC Pharma, Inc.: Form 10-Q for the period ended Jun 30, 2019

Filed with the SEC on Aug 9, 2019 and accepted by EDGAR at Aug 8, 2019, 21:29 ET.

Share

Management's discussion and analysis

As filed, 12,746 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The purpose of this Management’s Discussion and Analysis (“MD&A”) is to provide an understanding of the Company's consolidated financial condition, results of operations and cash flows, and should be read in conjunction with our unaudited condensed financial statements and related notes that appear elsewhere in this Quarterly Report on Form 10-Q for the three-months ended June 30, 2019, and the Annual Report on Form 10-K for the fiscal year ended March 31, 2019 filed with the SEC on June 14, 2019. The Company’s actual results could differ materially from those discussed here. Factors that could cause differences include those discussed in the “Forward-Looking Statements” section, as well as discussed elsewhere in this report. The risks and uncertainties can cause actual results to differ significantly from those in our forward-looking statements or implied in historical results and trends. We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Overview

Our primary source of revenue in the three-months ended June 30, 2019 and the three-months ended June 30, 2018 is from our Infrastructure Business. The Company’s Infrastructure Business, involves:

(i) Short-term rental of heavy construction equipment including bulldozers, excavators, rollers and pavers, among others.

(ii) Bidding and execution of construction contracts. Our subsidiary TBL, with over 30 years of experience with infrastructure projects, recently began work on a construction project, building and modifying a road in Kerala, India. In January 2019, TBL received a construction contract for the building of a National Highway Authority of India (“NHAI”) sponsored local highway for approximately $0.6 million.

(iii) The purchase and resale of physical commodities, used in infrastructure, such as steel, marble and tiles, among others.

Our second line of business is the Plant and Cannabinoid Business, which stems from plant material and cannabinoids produced by the cannabis plant. The Company’s strategy is to create, build, and manage several brands of plant and cannabinoid-based products and therapies, such as Hyalolex™, Serosapse™, Natrinol™, and Holi Hemp™, among others. As part of this strategy, the Company expects to secure the quantity, availability, and effective cost of its supply chain by setting up and controlling facilities that grow and extract the active ingredients for our products. In addition, we are also exploring acquisitions, investments, or the creation of joint ventures with competitive and complementary businesses, products and technologies. As market demand for hemp grows, as predicted by some analysts, we expect to sell these and other products on a retail and wholesale basis. As previously announced, our product mix is expected to include hemp/CBD-infused drinks including energy drink; tincture; full spectrum oil; hemp distillate; and hemp isolate, among others. The Company operates its Plant and Cannabinoid Business in compliance with federal, state, and local laws and only where it is legal to do so.

Results of Operations for the three months ended

June 30, 2019 and June 30, 2018

The historical results presented below are not necessarily indicative of the results that may be expected for any future period. The following table presents an overview of our results of operations for Fiscal 2019 and Fiscal 2018:

Statement of Operations (in thousands)

Three-months ended June 30, 2019 ($) 2018 ($) Change ($) Percent Change
Revenue 1,649 1,478 171 12%
Cost of revenue (1,608) (1,436) (172) 12%
General and administrative expenses (1,249) (517) (732) 142%
Research & development expenses (247) (36) (211) 586%
Operating loss (1,455) (511) (944) 185%
Other income/(expense), net 76 (1) 77 7700%
Net Loss (1,379) (512) (867) 169%

| June 30, 2019 Form 10-Q

Revenues– Revenue is primarily derived from our Infrastructure Business for the three months ended June 30, 2019 and the three months ended June 30, 2018. This amounted to approximately $1.65 million and $1.5 million, for the three months ended June 30, 2019 and three months ended June 30, 2018 respectively, representing an increase of $171 thousand or 12%. The increase in revenue is from an increase in the sales of infrastructure related physical commodities. In the three months ended March 31, 2019, we also commenced sales in the Plant and Cannabinoid Business, which contributed $104 thousand in revenue in the three months ended June 30, 2019.

Cost of revenue– Cost of revenue is primarily from our Infrastructure Business in the three months ended June 30, 2019 and the three months ended June 30, 2018. This amounts to approximately $1.6 million for the three months ended June 30, 2019 compared to $1.4 million in the three months ended June 30, 2018, an increase of approximately $172 thousand or 12%. This increase in cost of revenue is attributable to increased purchases of physical commodities, with the margins remaining stable. The Plant and Cannabinoid Business, contributed $91 thousand in cost of revenue in the three months ended June 30, 2019.

General and administrative expenses – These consist primarily of employee-related expenses, professional fees, legal fees, marketing, other corporate expenses, allocated general overhead and provisions, depreciation and write-offs relating to doubtful accounts and advances, if any. General and administrative expenses increased by approximately $732 thousand or 142% to $1.2 million for the three months ended June 30, 2019 from $517 thousand for the three months ended June 30, 2018. Of the $732 thousand increase, legal & professional fees, stemming from, among others, shareholder lawsuits, amounted to about $400 thousand.

Research and Development expenses - R&D expenses are attributed to our Plant and Cannabinoid Business. The expenses increased approximately $211 thousand or 586%, to $247 thousand for the three months ended June 30, 2019, compared to $36 thousand for the three months ended June 30, 2018. The cost associated with this work is mostly research comprising of plant extracts that could be productized and data to support the efficacy of the extracts. All research and development costs are expensed in the quarter in which they are incurred.

Other Income/(expense), net – Other income increased by approximately $77 thousand or 7700% during the three months ended June 30, 2019. The total other income for the three months ended June 30, 2019 and the three months ended June 30, 2018 is approximately $76 thousand and ($1) thousand, respectively. In the three months ended June 30, 2019, such amount includes interest income/(expense), rental income, dividend income, and a non-operating settlement expense.

Liquidity and Capital Resources

This liquidity and capital resources discussion compares the unaudited consolidated Company financials.

(in thousands, unaudited)

As of June 30, 2019 ($) As of March 31, 2019 ($) Change Percent Change
Cash, cash equivalents and marketable securities 16,554 25,610 (9,056) (35%)
Working capital 23,504 25,845 (2,341) (9%)

Cash and cash equivalents

Cash and cash equivalents decreased by approximately $9 million to $17 million in the three months ended June 30, 2019 from $26 million in March 31, 2019, a decrease of approximately 35%. The major decrease is due to investment of approximately $5 million in mutual funds and $1.7 million in inventory in the three months ended June 30, 2019.

Summary of Cash flows

(in thousands, unaudited)

Three Months Ended June 30, 2019 2018 Change Percent Change
Cash used in operating activities 2,872 535 2,337 437%
Cash used in investing activities 6,186 8 6,178 77225%
Cash used in financing activities - 67 (67) (100%)

| June 30, 2019 Form 10-Q

Operating Activities

Net cash used in operating activities for the three months ended June 30, 2019 was $2.9 million. Cash was consumed from continuing operations, with the net loss of $1.4 million, non-cash items totaling $225 thousand, consisting of a depreciation charge of $17 thousand and stock-based expenses totaling $208 thousand and changes in working capital accounts had a negative impact of $1,718 thousand on cash.

Net cash used in operating activities for the three months ended June 30, 2018 was $535 thousand. Cash was consumed from continuing operations, with the net loss of $512 thousand, non-cash items totaling $177 thousand, consisting of a depreciation charge of $15 thousand and stock-based expenses totaling $162 thousand and changes in working capital accounts had a negative impact of $200 thousand on cash

Investing Activities

Net cash used in investing activities during the three months ended June 30, 2019 was $6.2 million which is comprised of approximately $1,173 thousand for purchase of office space, plant and equipment among others, $5,009 thousand for investment in a money market mutual fund and $4 thousand of acquisition and filing of patents.

Net cash used in investing activities during the three months ended June 30, 2018 was $8 thousand which is comprised of approximately $3 thousand for purchase of plant and equipment among others, and $5 thousand of acquisition and filing of patents.

Financing Activities

There are no financing activities during the three months ended June 30, 2019.

Cash used in financing activities of approximately $67 thousand during the three months ended June 30, 2018 consisted of raising funds through a public offering amounted $134 thousand and repayment of loan amounted $201 thousand.

Off-Balance Sheet Arrangements

We do not have any outstanding derivative financial instruments, off-balance sheet guarantees, interest rate swap transactions or foreign currency forward contracts. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in an unconsolidated entity that provides financing, liquidity, market risk or credit support to us or that engages in leasing, hedging or research and development services with us.

Critical Accounting Policies

While all accounting policies impact the financial statements, certain policies may be viewed as critical. Critical accounting policies are those that are both most important to the portrayal of financial condition and results of operations and that require Management’s most subjective or complex judgments and estimates. Our Management believes the policies that fall within this category are the policies on revenue recognition, inventory, accounts receivable, income taxes, foreign currency translation, impairment of long-lived assets and investments, stock-based compensation, and cybersecurity. We have a cybersecurity policy in place and tighter cybersecurity measures to safeguard against hackers. There were no impactful breaches in cybersecurity in the three months ended June 30, 2019.

Please see our disclosures in Note 2 – Summary of Significant Accounting Policies to the Notes to the Unaudited Condensed Consolidated Financial Statements in this report, in the Notes to the Audited Consolidated Financial Statements in Part II of our Annual Report on Form 10-K for the fiscal year ended March 31, 2019 filed with the SEC on June 14, 2019, as well as Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations, on the same annual report, for a discussion of all our critical and significant accounting policies.

Recent Accounting Pronouncements

The recent accounting pronouncements are discussed in Note 2 – Summary of Significant Accounting Policies to the Notes to the Unaudited Condensed Consolidated Financial Statements in this report and in the Notes to the Audited Consolidated Financial Statements in Part II of our Annual Report on Form 10-K for fiscal year ended March 31, 2019 filed with the SEC on June 14, 2019.

Controls and procedures

As filed, 2,313 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

Our Management maintains disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act that are designed to provide reasonable assurance that information required to be disclosed in our reports filed or submitted under the Exchange Act is processed, recorded, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to Management, including our Chief Executive Officer and Principal Financial Officer (our principal executive officer and principal financial officer, respectively), as appropriate, to allow for timely decisions regarding required disclosure.

Our Management, including the Chief Executive Officer and Principal Financial Officer, carried out an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on this evaluation, our Chief Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were effective to ensure that the information required to be disclosed in the reports filed or submitted by us under the Exchange Act was recorded, processed, summarized and reported within the requisite time periods and that such information was accumulated and communicated to our Management, including our Chief Executive Officer and Principal Financial Officer, as appropriate to allow for timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

Our Management, including our Chief Executive Officer and Principal Financial Officer, evaluated our “internal control over financial reporting” as defined in Exchange Act Rule 13a-15(f) to determine whether any changes in our internal control over financial reporting occurred during the three months ended June 30, 2019 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Based on that evaluation, there were no changes in our internal control over financial reporting during the three months ended June 30, 2019 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

Risk factors

As filed, 250 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Incorporated by reference to our 2019 annual report on Form 10-K, filed with the SEC on June 14, 2019. Additionally, risks and uncertainty of which we are unaware or which currently we deem immaterial also may become important factor that affects us.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2019-04-01 to 2019-06-30$1.6mus-gaap:Revenues
Cost of revenue3 months2019-04-01 to 2019-06-30$1.6mus-gaap:CostOfRevenue
Gross profit3 months2019-04-01 to 2019-06-30$41.0kus-gaap:GrossProfit
Research and development3 months2019-04-01 to 2019-06-30$247.0kus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2019-04-01 to 2019-06-30$1.2mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2019-04-01 to 2019-06-30−$1.5mus-gaap:OperatingIncomeLoss
Income tax3 months2019-04-01 to 2019-06-30$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2019-04-01 to 2019-06-30−$1.4mus-gaap:NetIncomeLoss
Diluted EPS3 months2019-04-01 to 2019-06-30−$0.03us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow3 months2019-04-01 to 2019-06-30−$2.9mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2019-04-01 to 2019-06-30$1.2mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2019-06-30$16.6mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-06-30$24.6mus-gaap:AssetsCurrent
Total assetsAt period end2019-06-30$33.5mus-gaap:Assets
Current liabilitiesAt period end2019-06-30$1.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-06-30$1.1mus-gaap:Liabilities
Short-term borrowingsAt period end2019-06-30$50.0kus-gaap:ShortTermBorrowings
Shareholders' equityAt period end2019-06-30$32.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001185185-19-001094. Last ingested by Listed: Nov 6, 2026, 16:27 ET. Listed shows no prices and gives no investment advice.